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Available online 30 September 2015Long non-coding RNAs (lncRNAs) are subclass of noncoding RNAs that have been recently shown to play critical
roles in cancer biology. However, little is known about their mechanistic role in breast cancer pathogenesis, es-
pecially in triple-negative breast carcinomas (TNBC) that have particular poor outcomes.
This studywas speciﬁcally designed to identify the signatures relevant lncRNAs in breast cancer and characterize
lncRNAs thatmodulate the phenotype. Herewe provide detailedmethods and analysis ofmicroarray data,which
is deposited in the Gene Expression Omnibus (GEO) with the accession number GSE64790. The basic analysis as
contained in themanuscript published in Oncotargetwith the PMID 26078338. These data can be used to further
elucidate the mechanisms of breast cancer.
© 2015 Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).applicable, please follow the
ology.org/page/Main_Page
oarray V4.0 028,004
omas
apy prior to surgery. 3 paired sampleswere used formicroarray analysisConsent Informed consent and ethical approval obtainedfrom patients and ethical committee, respectively
Sample source location Taizhou, Zhejiang, China1. Direct link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE647902. Experimental design, materials and methods
2.1. Experimental design
Paired TNBC tissues and adjacent normal breast tissues from every
subject were obtained and used for long non-coding RNAs proﬁling.icle under the CC BY-NC-ND license (2.2. Materials and methods
2.2.1. Patient material
All patients are informed and have declared written informed con-
sent that their samples can be used for research. All patients received
tumor resection at Zhejiang Taizhou Hospital and were diagnosed
with TNBC histopathologically after surgery. Immunochemical staining
of estrogen receptor/progesterone receptor and ErbB2 receptor in 3
samples are shown in Fig. 1. There was no radiotherapy or chemother-
of lncRNAs. Demographic and clinical characterizations of the study
population are summarized in Table 1.
Tissue sections and specimenwere prepared by pathologists prior to
snap freezing and subsequent storage in liquid nitrogen prior to section-
ing. Biobanking and handling of the tissues followed the BRISQ guide-
lines. 20–30, 20 μm sections/sample (depending on tissue size) were
made in a cryotome and used for RNA extraction. All samples had at
least 80% tumor cell content.2.2.2. RNA isolation
Total RNA, including small RNAs, was isolated using the
mirVanaTM RNA Isolation Kit (Ambion, Foster City, CA, United
States) according to the manufacturer's instructions. RNA concentra-
tion was measured using the Nano Drop ND-2000 (Thermo Scientif-
ic), and RNA quality was evaluated on Agilent Bioanalyzer 2100
(Agilent Technologies). Only samples with an RNA Integrity Number
(RIN) greater than or equal to 7 were used for further downstream
processing.http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Immunochemical staining of estrogen receptor/progesterone receptor and ErbB2 receptor of 3 TNBC samples for microarray analysis.
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The sample labeling, microarray hybridization and washing were
performed based on the manufacturer's standard protocols. Brieﬂy,
mRNA was puriﬁed from total RNA after removal of rRNA by using an
mRNA-ONLY EukaryoticmRNA Isolation Kit (Epicenter Biotechnologies,
USA). Then, each sample was transcribed to double strand cDNA, then
synthesized into cRNA and labeled with Cyanine-3-CTP. The labeled
cRNAs were hybridized onto the Human lncRNA array V4.0Table 1
The demographic characteristics of 3 TNBC cases.
Patient number Patient code Sex Age (years)
1 WMY F 50
2 ZHX F 49
3 CYF F 46
Fig. 2. Representative box plot of raw data from three technical replicate hybridizations of a sing
which were further reﬁned during normalization. Overall, this points to high repeatability of te(4 × 180 K, Agilent), including the global proﬁling of 78,243 human
lncRNAs and 30,215 coding transcripts. After washing, the arrays were
scanned with the Agilent Scanner G2505C (Agilent Technologies).
2.2.4. Microarray data quality control
Since three technical replicate hybridizations were performed and
later averaged, care was taken to ensure high repeatability between
technical replicates. First, raw and normalized log2 data for each sampleDiagnosis Surgery date ER PR HER2
Breast cancer 2012.07.12 – – 1–2+
Breast cancer 2012.07.11 – – 2+
Breast cancer 2012.07.11 – – 2+
le sample. For all samples, the box plots revealedmedian-centered raw data distributions,
chnical replicate hybridizations.
Fig. 3. Representative scatter plot of data from three technical replicate hybridizations of a single sample. For all samples, the scatter plots revealed tight correlation between raw and nor-
malized data replicates, which overall, points to high repeatability of technical replicate hybridizations.
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were not included. A representative box plot is shown in Fig. 2. While
this analysis is designed to identify hybridizations that have intensity
distributions different from those of their technical replicates, we did
not ﬁnd any instances of this. This analysis also ensures that the normal-
ization has correctly centered the distributions of each replicate
microarray.
Next, we compared scatter plots of raw and normalized log2 data for
each sample using the R function pairs. Only data with a P-value detect-
ed b0.01 were included. A representative scatter plot is shown in Fig. 3.
Scatter plots were viewed in conjunction with Pearson correlation ta-
bles. Correlation values were calculated from both raw and normalized
log2 intensities for each technical repeat. Only probes with P-value de-
tected b0.01 were included in the calculation. Scatter plots conﬁrmed
high repeatability among technical replicates.
2.2.5. Data normalization
Feature Extraction software (version 10.7.1.1, Agilent Technologies)
was used to analyze array images and extract the raw data. Genespring
(Version 12.5, Agilent Technologies) was employed to ﬁnish the basic
analysis of the raw data. To begin with, the raw data were normalized
with the quantile algorithm. The probes that had at least 1 condition
out of 2 conditions ﬂagged as “P”were chosen for further data analysis.
Differentially expressed lncRNAs and mRNAs were then identiﬁed
through fold-change as well as P values calculated with t-test. The
threshold set for up- and down-regulated genes was fold change ≥2.0
and P value ≤0.05. Afterwards, hierarchical clustering was performed
to display the distinguishable lncRNAs and mRNAs expression patterns
among the samples.
2.2.6. Statistical analysis
The Statistical Program for Social Sciences (SPSS) 18.0 software
(SPSS, Chicago, IL, United States)was employed to performall the statis-
tical analyses. All data were expressed as themean± SD or proportions
where appropriate. For comparisons, paired t-tests and unpaired t-testswere performed where appropriate. P values of 0.05 (two-tailed) were
considered statistically signiﬁcant.
3. Discussion
TNBC accounts for approximately 10–25% of all breast cancers and is
of particular clinical interest due to its tendency to affect younger
women and refractory to currently available targeted therapy. The mo-
lecularmechanisms for aggressive clinical behavior of TNBC are not fully
understood [1–3]. We have described here a very unique data set of pa-
tients with triple-negative breast carcinomas. This data set is further
supported by additional clinical data that could be exploited in
deciphering clinical associations; however, the small sample size limits
this applicability. This data set has been used as a source of hypothesis
generation to discern and investigate lncRNAs that impact breast carci-
nomas. The outcome of such analyses has led to the generation of our
recent manuscript.
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